Prevalence of liver disease markers among patients with metabolic risk factors;Prevalencia markerov poškodenia pečene u pacientov s metabolickými rizikovými faktormi

Vnitrni Lekarstvi

Volumn 56, Issue 3, 2010, Pages 183-189

  Koller, T ^a   Kollerova J ^a   Hlavaty T ^a   Huorka, M ^a   Payer, J ^a  

^a FNsP Bratislava ^*  (Slovenia)

Author keywords

ALT; Diabetes mellitus; GGT; Hypertension; Obesity; Prevalence; Screening; Steatosis

Indexed keywords

ALANINE AMINOTRANSFERASE; BIOLOGICAL MARKER; GAMMA GLUTAMYLTRANSFERASE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DYSLIPIDEMIA; FATTY LIVER; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OBESITY; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR; ULTRASOUND; FEMALE; MALE; METABOLIC SYNDROME X; MIDDLE AGED;

BIOLOGICAL MARKERS; FATTY LIVER; FEMALE; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; RISK FACTORS;

EID: 77950971889     PISSN: 0042773X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Mokáň M, Galajda P, Prídavková D et al. Prevalence of diabetes mellitus and metabolic syndrome in Slovakia. Diabetes Res Clin Pract 2008; 81: 238-242.
2. Marchesini G, Bugianesi E, Forlani G et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003; 37: 917-923.
3. Hůlek P, Dresslerová I. Metabolický syndrom a játra (NAFLD/NASH). Vnitř Lék 2009; 55: 646-649.
4. Koller T. Diagnostika a manažment pacientov s nealkoholovou tukovou chorobou pečene. Čes Slov Gastroenterol Hepatol 2007; 61: 96-102.
5. Argo CK, Caldwell SH. Epidemiology and natural history of non-alcoholic steatohepatitis. Clin Liver Dis 2009; 13: 511-531.
6. Ruhl CE, Everhart JE. Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States. Gastroenterology 2003; 124: 71-79. (Pubitemid 36055340)
7. André P, Balkau B, Vol S et al. DESIR Study Group. Gamma-glutamyltransferase activity and development of the metabolic syndrome. (International Diabetes Federation Definition) in middle-aged men and women: Data from the Epidemiological Study on the Insulin Resistance Syndrome (DESIR) cohort. Diabetes Care 2007; 30: 2355-2361.
8. Wannamethee SG, Shaper AG, Lennon L et al. Hepatic enzymes, the metabolic syndrome, and the risk of type 2 diabetes in older men. Diabetes Care 2005; 12: 2913-2918.
9. Lee DS, Evans JC, Robins SJ et al. Gamma glutamyl transferase and metabolic syndrome, cardiovascular disease, and mortality risk: the Framingham Heart Study. Arterioscler Thromb Vasc Biol 2007; 27: 127-133.
10. Kang YH, Min HK, Son SM et al. The association of serum gamma glutamyltransferase with components of the metabolic syndrome in the Korean adults. Diabetes Res Clin Pract 2007; 77: 306-313.
11. Browning JD. Statins and hepatic steatosis: perspectives from the Dallas Heart Study. Hepatology 2006; 44: 466-471.
12. Sanyal AJ. American Gastroenterological Association. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 2002; 123: 1705-1725.
13. Gupte P, Amarapurkar D, Agal S et al. Non-alcoholic steatohepatitis in type 2 diabetes mellitus. J Gastroenterol Hepatol 2004; 19: 854-858. (Pubitemid 39093200)
14. Kogiso T, Moriyoshi Y, Nagahara H. Clinical significance of fatty liver associated with metabolic syndrome. Hepatol Res 2007; 37: 711-721. (Pubitemid 47054777)
15. Targher G, Bertolini L, Rodella S et al. Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients. Diabetes Care 2007; 30: 2119-2121. (Pubitemid 47219432)
16. Hamaguchi M, Kojima T, Takeda N et al. Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. World J Gastroenterol 2007; 13: 1579-1584. (Pubitemid 46672668)
17. Siegel AB, Zhu AX. Metabolic syndrome and hepatocellular carcinoma: two growing epidemics with a potential link. Cancer 2009; 115: 5651-5661.
18. Angulo P. Noninvasive assessment of fibrosis and steatosis in NASH and ASH. Gastroenterol Clin Biol 2009; 33: 940-948.
19. Vuppalanchi R, Chalasani N. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management. Hepatology 2009; 49: 306-317.